Kalvista Pharmaceuticals (NASDAQ: MDCO) and The Medicines (NASDAQ:MDCO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Risk & Volatility

Kalvista Pharmaceuticals has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500. Comparatively, The Medicines has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Earnings & Valuation

This table compares Kalvista Pharmaceuticals and The Medicines’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kalvista Pharmaceuticals $8.39 million 24.23 -$15.80 million ($1.53) -10.56
The Medicines $44.79 million 56.08 -$708.37 million ($8.40) -4.05

Kalvista Pharmaceuticals has higher earnings, but lower revenue than The Medicines. Kalvista Pharmaceuticals is trading at a lower price-to-earnings ratio than The Medicines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kalvista Pharmaceuticals and The Medicines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kalvista Pharmaceuticals -188.29% -55.65% -32.66%
The Medicines -668.93% -394.33% -33.65%

Analyst Ratings

This is a breakdown of current recommendations for Kalvista Pharmaceuticals and The Medicines, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalvista Pharmaceuticals 0 0 2 0 3.00
The Medicines 0 0 7 0 3.00

Kalvista Pharmaceuticals presently has a consensus target price of $23.50, indicating a potential upside of 45.42%. The Medicines has a consensus target price of $53.86, indicating a potential upside of 58.22%. Given The Medicines’ higher probable upside, analysts plainly believe The Medicines is more favorable than Kalvista Pharmaceuticals.

Institutional and Insider Ownership

50.3% of Kalvista Pharmaceuticals shares are held by institutional investors. 38.4% of Kalvista Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of The Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kalvista Pharmaceuticals beats The Medicines on 8 of the 13 factors compared between the two stocks.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.

About The Medicines

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.